DE156354T1 - Kontrollierte oxydation von mikrobiell hergestellten cysteine enthaltenden proteinen. - Google Patents
Kontrollierte oxydation von mikrobiell hergestellten cysteine enthaltenden proteinen.Info
- Publication number
- DE156354T1 DE156354T1 DE198585103559T DE85103559T DE156354T1 DE 156354 T1 DE156354 T1 DE 156354T1 DE 198585103559 T DE198585103559 T DE 198585103559T DE 85103559 T DE85103559 T DE 85103559T DE 156354 T1 DE156354 T1 DE 156354T1
- Authority
- DE
- Germany
- Prior art keywords
- protein
- synthetic
- useful
- biological activity
- cystine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/811—Interferon
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/141—Interleukin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/142—Interferon
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Claims (10)
1. Verfahren zur gesteuerten Oxidation eines vollständig
reduzierten mikrobiologisch hergestellten synthetischen Proteins mit einer Aminosäuresequenz die im wesentlichen
mit der eines nützlichen Proteins identisch ist, dessen Sequenz Cysteinreste enthält, die in dem nützlichen Protein
intramolekular zu einem Cystinrest verbunden sind, wobei die Cysteinreste unter geringst möglicher Über-Oxidation
und Bildung nicht der Konformation entsprechender Cystinreste oder Oligomere selektiv zu Cystinresten
oxidiert werden, dadurch gekennzeichnet, daß man das vollständig reduzierte mikrobiologisch hergestellte
synthetische Protein mit o-Iodosobenzoesäureester in einer wässrigen Phase umsetzt, in der der pH-Wert mindestens
eine halbe pH-Einheit unter dem pK -Wert der genannten
Cysteine liegt und in der die Konzentration des synthetischen Proteins im Reaktionsgemisch weniger als
etwa 5 mg/ml beträgt und das Molverhältnis von o-Iodosobenzoesäure
zu Protein mindestens stöchiometrisch ist,
unter der Voraussetzung, daß der o-Iodosobenzoesäureester
im letzten Abschnitt der Umsetzung im Überschuß enthalten ist.
2. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß
das nützliche Protein ein natürliches Protein mit einer nützlichen biologischen Aktivität ist und die intramolekulare
Verbindung wesentlich für die biologische
Aktivität ist oder die biologische Aktivität erhöht. 35
3. Verfahren nach einem der Ansprüche 1 oder 2, dadurch gekennzeichnet, daß das Protein ß-IFN oder IL-2 ist.
4. Verfahren nach einem der Ansprüche 1 - 3, dadurch ge-
kennzeichnet, daß der pH-Wert zwischen 5,5 und 9 liegt.
5. Verfahren nach einem der Ansprüche 1-4, dadurch gekennzeichnet,
daß die Konzentration des synthetischen Proteins im Bereich zwischen etwa 0,3 bis etwa 0,7 mg/ml
liegt.
6. Verfahren nach einem der Ansprüche 1-5, dadurch gekennzeichnet,
daß nach der Oxidation das oxidierte Produkt mit einem GeIfiltrations-Verfahren gereinigt wird.
7. Ein oxidiertes Präparat eines synthetischen Proteins mit einer Aminosäuresequenz, die im wesentlichen mit
der eines nützlichen Proteins identisch ist, dessen Sequenz Cysteinreste enthält, die in dem nützlichen Protein
intramolekular zu einem Cystinrest verbunden sind, dadurch gekennzeichnet, daß es
(I) dieselbe Disulfidbrücke wie das natürliche nützliche
Protein aufweist;
(II) im wesentlichen frei von Oligomeren ist; und
(III) weniger als etwa 15 Gewichtsprozent Isomere ententhält, die vom natürlichen nützlichen Protein
unterschiedliche Disulfidbrücken aufweisen.
8. Präparat nach Anspruch 7, dadurch gekennzeichnet, daß es weniger als etwa 1 Gewichtsprozent Oligomere enthält.
9. Präparat nach einem der Ansprüche 7 oder 8, dadurch gekennzeichnet,
daß das synthetische Protein ein synthetisches Mutein eines biologisch aktiven Proteins ist,
das mindestens einen zur Bildung einer Disulfidbindung
1 freien Cysteinrest enthält, der für die biologische Aktivität unwesentlich ist, wobei im Mutein mindestens
einer der Cysteinreste deletiert ist oder durch eine andere Aminosäure ersetzt ist.
10. Präparat nach einem der Ansprüche 7-9, dadurch gekennzeichnet,
daß das synthetische Protein ß-IFN oder IL-2 ist.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59435184A | 1984-03-28 | 1984-03-28 | |
US06/661,902 US4530787A (en) | 1984-03-28 | 1984-10-17 | Controlled oxidation of microbially produced cysteine-containing proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
DE156354T1 true DE156354T1 (de) | 1986-03-20 |
Family
ID=27081941
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE198585103559T Pending DE156354T1 (de) | 1984-03-28 | 1985-03-26 | Kontrollierte oxydation von mikrobiell hergestellten cysteine enthaltenden proteinen. |
DE3587873T Expired - Lifetime DE3587873T2 (de) | 1984-03-28 | 1985-03-26 | Kontrollierte Oxydation von mikrobiell hergestellten Cysteine enthaltenden Proteinen. |
DE3588226T Expired - Lifetime DE3588226D1 (de) | 1984-03-28 | 1985-03-26 | Kontrollierte Oxidation von mikrobiell herstellten, Cystein-enthaltenden Proteinen |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE3587873T Expired - Lifetime DE3587873T2 (de) | 1984-03-28 | 1985-03-26 | Kontrollierte Oxydation von mikrobiell hergestellten Cysteine enthaltenden Proteinen. |
DE3588226T Expired - Lifetime DE3588226D1 (de) | 1984-03-28 | 1985-03-26 | Kontrollierte Oxidation von mikrobiell herstellten, Cystein-enthaltenden Proteinen |
Country Status (5)
Country | Link |
---|---|
US (1) | US4530787A (de) |
EP (2) | EP0606673B1 (de) |
AT (2) | ATE108186T1 (de) |
CA (1) | CA1233172A (de) |
DE (3) | DE156354T1 (de) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4925919A (en) * | 1984-04-25 | 1990-05-15 | Roland Mertelsmann | Purified interleukin 2 |
US4992271A (en) * | 1982-09-23 | 1991-02-12 | Cetus Corporation | Formulation for lipophilic IL-2 proteins |
US4853332A (en) * | 1982-10-19 | 1989-08-01 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins |
JPS60115528A (ja) * | 1983-11-28 | 1985-06-22 | Takeda Chem Ind Ltd | ヒトインタ―ロイキン―2蛋白質を含有する抗腫瘍用または免疫機能低下疾患治療用組成物 |
US4604377A (en) * | 1984-03-28 | 1986-08-05 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
US4569790A (en) * | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
DE3583880D1 (de) * | 1984-04-09 | 1991-10-02 | Takeda Chemical Industries Ltd | Stabile interleukin-2-zusammensetzung. |
US4908433A (en) * | 1984-04-25 | 1990-03-13 | Sloan-Kettering Institute For Cancer Research | Uses of interleukin-2 |
US4908434A (en) * | 1984-04-25 | 1990-03-13 | Sloan-Kettering Institute For Cancer Research | Process for preparing purified interleukin-2 |
US4761375A (en) * | 1984-05-08 | 1988-08-02 | Genetics Institute, Inc. | Human interleukin-2 cDNA sequence |
US4572798A (en) * | 1984-12-06 | 1986-02-25 | Cetus Corporation | Method for promoting disulfide bond formation in recombinant proteins |
CA1340265C (en) | 1985-01-18 | 1998-12-15 | Kirston E. Koths | Oxidation resistant muteins |
US5248769A (en) * | 1985-06-26 | 1993-09-28 | Cetus Oncology Corporation | Process for recovering refractile bodies containing heterologous proteins from microbial hosts |
US4748234A (en) * | 1985-06-26 | 1988-05-31 | Cetus Corporation | Process for recovering refractile bodies containing heterologous proteins from microbial hosts |
US4690915A (en) * | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
DE3537708A1 (de) * | 1985-10-23 | 1987-04-23 | Boehringer Mannheim Gmbh | Verfahren zur aktivierung von t-pa nach expression in prokaryonten |
US4766205A (en) * | 1985-11-13 | 1988-08-23 | Beatrice Companies, Inc. | Method for isolation of recombinant polypeptides in biologically active forms |
US4933433A (en) * | 1986-01-31 | 1990-06-12 | E. I. Du Pont De Nemours And Company | Recombinant interleukin-2 composition and process for making it |
CA1291706C (en) * | 1986-04-03 | 1991-11-05 | Alfred Rudolph | COMBINATION THERAPY USING INTERFERON-.beta. AND INTERLEUKIN-2 |
DE3611817A1 (de) * | 1986-04-08 | 1987-10-15 | Boehringer Mannheim Gmbh | Verfahren zur renaturierung von proteinen |
US5425940A (en) * | 1986-04-09 | 1995-06-20 | Cetus Oncology Corporation | Combination therapy using interleukin-2 and tumor necrosis factor |
US4777242A (en) * | 1986-10-10 | 1988-10-11 | Phillips Petroleum Company | Purification of recombinant tumor necrosis factor |
US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
CA1339757C (en) * | 1987-04-16 | 1998-03-17 | Robert F. Halenbeck | Production of purified biologically active, bacterially produced recombinant human csf-1 |
US4929700A (en) * | 1987-04-16 | 1990-05-29 | Cetus Corporation | Production of purified, biologically active, bacterially produced recombinant human CSF-1 |
AU621051B2 (en) * | 1987-04-28 | 1992-03-05 | Amgen, Inc. | Method for purifying granulocyte-macrophage colony stimulating factor |
ATE156491T1 (de) * | 1987-05-11 | 1997-08-15 | Chiron Corp | Prozess zur gewinnung von gereinigtem, oxidiertem, renaturiertem, rekombinantem interleukin-2 aus mikroorganismen |
US4961969A (en) * | 1987-05-11 | 1990-10-09 | Cetus Corporation | Process for recovering microbially produced interferon-β |
US4931543A (en) * | 1987-05-11 | 1990-06-05 | Cetus Corporation | Process for recovering microbially produced interleukin-2 |
US4801691A (en) * | 1987-05-15 | 1989-01-31 | International Minerals & Chemical Corp. | Method for removing sodium dodecyl sulfate from sodium dodecyl sulfate solubilized protein solutions |
US4985544A (en) * | 1987-08-04 | 1991-01-15 | Kyowa Hakko Kogyo Co., Ltd. | Process for renaturing fish growth hormone |
US5004605A (en) * | 1987-12-10 | 1991-04-02 | Cetus Corporation | Low pH pharmaceutical compositions of recombinant β-interferon |
US5759815A (en) * | 1988-02-11 | 1998-06-02 | Creative Biomolecules, Inc. | Production of platelet derived growth factor (PDGF) an muteins thereof |
CA1340586C (en) * | 1988-09-23 | 1999-06-08 | Cetus Corporation | Process for recovering microbially produced interferon-beta |
JP2682061B2 (ja) * | 1988-10-07 | 1997-11-26 | 藤沢薬品工業株式会社 | ペプチドの分子内ジスルフィド結合の形成法 |
US5204256A (en) * | 1989-09-06 | 1993-04-20 | Behringwerke Aktiengesellschaft | Process for the purification of plasminogen activator inhibitor 2 (pai-2) |
US5023323A (en) * | 1990-09-12 | 1991-06-11 | Monsanto Company | Method of somatotropin naturation |
US5830452A (en) * | 1990-11-20 | 1998-11-03 | Chiron Corporation | Method for enhancing the anti-tumor therapeutic index of interleukin-2 |
JP3021040B2 (ja) * | 1990-11-23 | 2000-03-15 | ヘキスト・マリオン・ルセル | 少なくとも1個の分子内ジスルフィド結合を含有する蛋白質を相当する還元された組替え蛋白質を5.0以下のpHで酸化することによって製造する方法 |
DE4105480A1 (de) * | 1991-02-21 | 1992-08-27 | Boehringer Mannheim Gmbh | Verbesserte aktivierung von rekombinanten proteinen |
US6063764A (en) * | 1992-06-01 | 2000-05-16 | Washington University & Chiron Corp. | Method for using lipoprotein associated coagulation inhibitor to treat sepsis |
US20030171292A1 (en) * | 1992-06-01 | 2003-09-11 | Creasey Abla A. | Method for using lipoprotein associated coagulation inhibitor to treat sepsis |
EP0672144A1 (de) * | 1992-10-20 | 1995-09-20 | Chiron Corporation | Interleukin-6-receptor-antagonisten |
US5545723A (en) * | 1994-03-15 | 1996-08-13 | Biogen Inc. | Muteins of IFN-β |
EP1935431A3 (de) | 2000-05-15 | 2008-08-13 | Health Research, Inc. | Krebsbehandlungen unter Verwendung einer Kombination aus einem HER2-Antikörper und Interleukin-2 |
ATE418542T1 (de) | 2001-03-29 | 2009-01-15 | Schering Corp | Als ccr5-antagonisten verwendbare aryloxim- piperazine |
US6887462B2 (en) | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
AU2002365131B2 (en) * | 2001-10-15 | 2007-03-01 | Novartis Vaccines And Diagnostics, Inc. | Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (TFPI) |
RU2344128C2 (ru) | 2003-03-24 | 2009-01-20 | Ф.Хоффманн-Ля Рош Аг | Бензилпиридазиноны как ингибиторы обратной транскриптазы |
MXPA06000460A (es) | 2003-07-11 | 2006-04-07 | Schering Ag | Polipeptidos humanos, recombinantes, mejorados de interferon-beta-1b. |
ATE473016T1 (de) | 2003-11-04 | 2010-07-15 | Novartis Vaccines & Diagnostic | Verfahren zur behandlung von krebs mit expression des cd40-antigens |
CN101426520A (zh) * | 2004-03-17 | 2009-05-06 | 诺华疫苗和诊断公司 | 通过给予组织因子途径抑制剂(tfpi)治疗社区获得性重症肺炎 |
ES2318916B1 (es) * | 2005-02-07 | 2010-03-22 | Chiron Corporation | Procedimiento para preparar aldesleukina para uso farmaceutico. |
CN101291905A (zh) | 2005-10-19 | 2008-10-22 | 弗·哈夫曼-拉罗切有限公司 | 苯乙酰胺nnrt抑制剂 |
ES2360893T3 (es) | 2006-08-16 | 2011-06-10 | F. Hoffmann-La Roche Ag | Inhibidores no nucleósidos de la transcriptasa inversa. |
RU2469032C2 (ru) | 2006-12-13 | 2012-12-10 | Ф.Хоффманн-Ля Рош Аг | Производные 2-(пиперидин-4-ил)-4-фенокси- или фениламинопиримидина в качестве ненуклеозидных ингибиторов обратной транскриптазы |
JP5167350B2 (ja) | 2007-05-30 | 2013-03-21 | エフ.ホフマン−ラ ロシュ アーゲー | 非ヌクレオシド系逆転写酵素阻害剤 |
WO2009045553A1 (en) * | 2007-10-05 | 2009-04-09 | Barofold, Inc. | High pressure treatment of aggregated interferons |
CN101903382B (zh) | 2007-12-21 | 2012-11-28 | 弗·哈夫曼-拉罗切有限公司 | 杂环抗病毒化合物 |
AU2011229491B2 (en) | 2010-03-17 | 2015-02-05 | Ratiopharm Gmbh | Method for obtaining biologically active recombinant human G-CSF |
EP2655409A4 (de) | 2010-12-22 | 2015-07-01 | Univ Leland Stanford Junior | Superagonisten und antagonisten von interleukin-2 |
KR102220006B1 (ko) | 2011-03-11 | 2021-02-24 | 아시스땅스 퍼블리끄-오삐또 드 빠리 | 자가면역 - 관련 또는 염증성 장애를 치료하기 위한 저용량 il2 의 용도 |
EP2768844B1 (de) * | 2011-10-21 | 2016-04-27 | Tanvex Biologics Corp. | Trennung acetylierter proteine von nichtacetylierten proteinen |
WO2014206899A1 (en) | 2013-06-25 | 2014-12-31 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Boosting treg cells for treating alzheimer disease and related disorders |
EP3049445A4 (de) | 2013-09-24 | 2017-10-25 | Medicenna Therapeutics, Inc. | Interleukin-2-fusionsproteine und verwendungen davon |
EP2918285A1 (de) | 2014-03-11 | 2015-09-16 | Université Pierre et Marie Curie (Paris 6) | Interleukin-2 zur Behandlung einer Lebensmittelallergie |
US10150802B2 (en) | 2014-04-24 | 2018-12-11 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
US10457716B2 (en) | 2014-08-06 | 2019-10-29 | University Of Notre Dame Du Lac | Protein folding and methods of using same |
CA2963602A1 (en) | 2014-10-09 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Multiple-variable il-2 dose regimen for treating immune disorders |
WO2017068031A1 (en) * | 2015-10-22 | 2017-04-27 | Iltoo Pharma | Pharmaceutical compositions of il-2 |
WO2018170288A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
CN111010866A (zh) | 2017-05-24 | 2020-04-14 | 潘迪恩治疗公司 | 靶向免疫耐受性 |
CN111201035A (zh) | 2017-06-19 | 2020-05-26 | 梅迪塞纳医疗股份有限公司 | Il-2超激动剂、激动剂及其融合体的用途和方法 |
AU2018372167B2 (en) | 2017-11-21 | 2023-12-07 | The Board Of Trustees Of The Leland Stanford Junior University | Partial agonists of interleukin-2 |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
WO2019158764A1 (en) | 2018-02-16 | 2019-08-22 | Iltoo Pharma | Use of interleukin 2 for treating sjögren's syndrome |
WO2020007937A1 (en) | 2018-07-03 | 2020-01-09 | Iltoo Pharma | Use of interleukin-2 for treating systemic sclerosis |
EP3836954A1 (de) | 2018-08-13 | 2021-06-23 | Iltoo Pharma | Kombination von interleukin-2 mit einem interleukin-1-inhibitor, konjugate und therapeutische verwendungen davon |
JP2022533702A (ja) | 2019-05-20 | 2022-07-25 | パンディオン・オペレーションズ・インコーポレイテッド | MAdCAM標的化免疫寛容 |
JP7303391B2 (ja) | 2020-01-14 | 2023-07-04 | シンセカイン インコーポレイテッド | バイアス型il2ムテイン、方法、および組成物 |
WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
WO2021176044A1 (en) | 2020-03-06 | 2021-09-10 | Centre Hospitalier Universitaire De Nimes | Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis |
WO2024121173A1 (en) | 2022-12-05 | 2024-06-13 | Centre Hospitalier Universitaire De Nimes | Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis in a subgroup of patients |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4061538A (en) * | 1973-04-04 | 1977-12-06 | Sandoz Ltd. | Enzymatically oxidizing interferon |
CH648331A5 (de) * | 1979-07-31 | 1985-03-15 | Hoffmann La Roche | Homogenes fibroblasten-interferon und dessen herstellung. |
US4414147A (en) * | 1981-04-17 | 1983-11-08 | Massachusetts Institute Of Technology | Methods of decreasing the hydrophobicity of fibroblast and other interferons |
US4411993A (en) * | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
US4405601A (en) * | 1981-05-21 | 1983-09-20 | Cancer Research Center | Extraction and purification of biologically active lymphokines |
US4478744A (en) * | 1982-01-25 | 1984-10-23 | Sherwood Medical Company | Method of obtaining antibodies |
US4450103A (en) * | 1982-03-01 | 1984-05-22 | Cetus Corporation | Process for recovering human IFN-β from a transformed microorganism |
DE3377363D1 (en) * | 1982-03-31 | 1988-08-18 | Ajinomoto Kk | Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells |
DE3378128D1 (en) * | 1982-04-20 | 1988-11-03 | Sloan Kettering Inst Cancer | Purification of interleukin 2 |
JPS58201794A (ja) * | 1982-05-17 | 1983-11-24 | Toray Ind Inc | ヒトインターフェロンβの濃縮精製法 |
US4462940A (en) * | 1982-09-23 | 1984-07-31 | Cetus Corporation | Process for the recovery of human β-interferon-like polypeptides |
IE56026B1 (en) * | 1982-10-19 | 1991-03-27 | Cetus Corp | Cysteine-depleted muteins of biologically active proteins |
US4432895A (en) * | 1982-11-24 | 1984-02-21 | Hoffmann-La Roche Inc. | Monomeric interferons |
GR79124B (de) * | 1982-12-22 | 1984-10-02 | Genentech Inc | |
DE122080T1 (de) * | 1983-03-25 | 1985-05-23 | Celltech Ltd., Slough, Berkshire | Verfahren zur herstellung eines proteins. |
GB8317880D0 (en) * | 1983-07-01 | 1983-08-03 | Searle & Co | Structure and synthesis of interferons |
US4569790A (en) * | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
-
1984
- 1984-10-17 US US06/661,902 patent/US4530787A/en not_active Expired - Lifetime
- 1984-11-28 CA CA000468868A patent/CA1233172A/en not_active Expired
-
1985
- 1985-03-26 EP EP93203286A patent/EP0606673B1/de not_active Expired - Lifetime
- 1985-03-26 DE DE198585103559T patent/DE156354T1/de active Pending
- 1985-03-26 DE DE3587873T patent/DE3587873T2/de not_active Expired - Lifetime
- 1985-03-26 AT AT85103559T patent/ATE108186T1/de not_active IP Right Cessation
- 1985-03-26 AT AT93203286T patent/ATE196769T1/de not_active IP Right Cessation
- 1985-03-26 EP EP85103559A patent/EP0156354B1/de not_active Expired - Lifetime
- 1985-03-26 DE DE3588226T patent/DE3588226D1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US4530787A (en) | 1985-07-23 |
EP0156354A2 (de) | 1985-10-02 |
CA1233172A (en) | 1988-02-23 |
EP0606673B1 (de) | 2000-10-04 |
DE3587873T2 (de) | 1994-10-20 |
US4530787B1 (de) | 1993-07-20 |
EP0606673A2 (de) | 1994-07-20 |
DE3587873D1 (de) | 1994-08-11 |
EP0606673A3 (de) | 1995-01-25 |
EP0156354A3 (en) | 1987-10-28 |
ATE108186T1 (de) | 1994-07-15 |
ATE196769T1 (de) | 2000-10-15 |
EP0156354B1 (de) | 1994-07-06 |
DE3588226D1 (de) | 2000-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE156354T1 (de) | Kontrollierte oxydation von mikrobiell hergestellten cysteine enthaltenden proteinen. | |
EP0207956B1 (de) | Hirudin-pa und dessen derivate, verfahren zu deren herstellung und deren verwendung | |
DE3203775A1 (de) | Fibrinogenzubereitung, verfahen zu ihrer herstellungund ihre verwendung | |
EP0464867A1 (de) | Fusionsproteine aus Interleukin-2 und Hirudin | |
DE3485945T2 (de) | Gereinigter transformierender wachstum-beta-faktor aus humanen plaketten und plazenten stammend. | |
KR860005015A (ko) | 재조합 단백질에서 디설파이드 결합형성을 촉진시키는 방법 | |
ES2000216A6 (es) | Procedimiento para preparar un polipeptido purificado que tiene propiedades inhibidoras de la coagulacion de la sangre. | |
ATE61407T1 (de) | Muteine biologisch aktiver proteine mit verringertem cysteingehalt, ihre herstellung, formulierungen, die solche muteine enthalten sowie strukturgene, vektoren und organismen, die zur herstellung der genannten muteine geeignet sind und deren herstellung. | |
IE850983L (en) | Polypeptides with an anticoagulant action | |
DE3483227D1 (de) | Protein mit zellwachstumsstimulierender wirkung, dessen zusammensetzung und verfahren zu seiner herstellung. | |
CH641046A5 (de) | Verfahren zur herstellung bestaendiger urokinasemittel. | |
EP0018353A1 (de) | Verfahren zur Herstellung von nebenwirkungsfreien Plasmafraktionen | |
DE68915226T2 (de) | Thrombin bindende Substanz und Verfahren zu ihrer Herstellung. | |
DE3506992A1 (de) | Modifizierte hirudine, verfahren zu deren herstellung und pharmazeutische mittel, die diese wirkstoffe enthalten | |
DE69911024T2 (de) | Methoden zur herstellung von rekombinanten peptiden mit einer geringen menge von trisulfiden | |
DE2540544C2 (de) | (1-47)-Urogastron und das entsprechende durch Reduktion der Disulfidbindungen erhältliche Polypeptid, Verfahren zu deren Herstellung und diese Polypeptide enthaltende pharmazeutische Zusammensetzungen | |
EP0381958B1 (de) | Verfahren zur Herstellung eines Insulinvorläufers | |
DE69408631T2 (de) | Verfahren zur reinigung eines hydrophoben polypeptides | |
DE3687995D1 (de) | Verfahren zur reinigung von interferon und so hergestellte zusammensetzung. | |
DE2540545C2 (de) | (1-46)-Urogastron und das entsprechende durch Reduktion der Disulfidbindungen erhältliche Polypeptid, Verfahren zu deren Herstellung und diese Polypeptide enthaltende pharmazeutische Zusammensetzungen | |
ATE44750T1 (de) | Verfahren zur herstellung eines antihaemophiliefaktor-konzentrats. | |
DE69209486T2 (de) | Stabilisierte pharmaceutische Zusammensetzung die nicht-glycozylierte, reduzierte rekombinante human IL-2 umfasst und Verfahren zu ihrer Herstellung | |
DE59309129D1 (de) | Verfahren zur elektrochemischen herstellung von adipinsäure | |
DE69031596T2 (de) | Verfahren zur herstellung eines proteins gehörend zu der klasse der cytokine, das mindestens eine intramolekulare disulfidbrücke enthält, durch oxidation bei einem ph-wert kleiner als 5.0 des entsprechenden rekombinanten reduzierten proteins | |
WO1991006560A1 (de) | Quervernetzte tumor-nekrose-faktoren |